08:27 AM EDT, 03/24/2026 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) said Tuesday that it has completed its acquisition of Clario for about $8.88 billion in cash, plus additional payments linked to performance-based milestones.

Along with the initial cash payment at closing, Thermo Fisher said it will pay $125 million in January 2027 and up to $400 million of earnout payments based on Clario's performance in 2026 and 2027.

The company said it continues to expect the acquisition to contribute $0.45 to adjusted earnings per share in year one after closing and realize about $175 million in adjusted operating income from synergies by year five.

Clario, a provider of endpoint data tools for clinical trials, will join Thermo Fisher's Laboratory Products and Biopharma Services segment, according to Thermo Fisher.